CGTLive’s Weekly Rewind – June 10, 2022

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Eli-Cel Earns Unanimous FDA AdComm Vote Supporting Risk-Benefit in CALD

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted in favor of the benefits of bluebird bio's eli-cel in patients with cerebral andrenoleukodystrophy despite substantial safety concerns.

2. Frederick Locke, MD, on the Impact Potential of CAR T-Cell Therapies in Hematologic Malignancies

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed positive data seen with tisa-cel, liso-cel, ide-cel, cilta-cel, and brexu-cel.

3. Allogeneic CAR T-Cell Therapy Yields 100% CR Rate in B-NHL

Caribou Biosciences’ CB-010, an allogeneic chimeric antigen receptor (CAR) T cell therapy, has demonstrated efficacy in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) with a 100% complete responses (CR) rate.

4. Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors

The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.

5. Exploring New Paths for CAR T-Cell Therapy Research in Multiple Myeloma

Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.